Valiant Laboratories

Valiant Laboratories CapEx/D&A

The CapEx to Depreciation Ratio of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 54.41. In the previous year, CapEx to Depreciation Ratio was 23.34 — a change of 133.14% (higher).

CapEx/D&A

54.41

YoY

133.14%

Last updated:

CapEx to Depreciation Ratio of Valiant Laboratories is 2025 54.41 . CapEx to Depreciation Ratio of Valiant Laboratories was 2024 23.34 . It decreases by 133.14% higher compared to the previous year.

The Valiant Laboratories CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2022
4.24 INR
Jan 1, 2023
24.15 INR
Jan 1, 2024
23.34 INR
Jan 1, 2025
54.41 INR
The Valiant Laboratories CapEx/D&A history
YEARCapEx/D&AYoY
54.41+133.14%
23.34-3.39%
24.15+469.08%
4.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

CapEx to Depreciation Ratio of Valiant Laboratories is 54.41 in 2025.

CapEx to Depreciation Ratio of Valiant Laboratories changed from 23.34 to 54.41, representing a 133.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valiant Laboratories

All Key Metrics — Valiant Laboratories